^
    Back
    Association details:
    Biomarker:EPHA2 overexpression + EGFR overexpression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR-II 2020
    Title:

    Abstract 4296: The EphA2/EGFR pathway dysregulation associates with poor prognosis and cetuximab treatment response in colorectal cancer

    Published date:
    05/15/2020
    Excerpt:
    ...EphA2 and EGFR overexpression showed a combined effect relative to cetuximab resistance, independently from KRAS mutation status.
    DOI:
    10.1158/1538-7445.AM2020-4296